{"title":"产后抑郁症及其他症状的神经类固醇治疗","authors":"Kristina M. Deligiannidis, Samantha Meltzer-Brody","doi":"10.1192/bjp.2025.90","DOIUrl":null,"url":null,"abstract":"<p>Depression occurring during pregnancy or after delivery is one of the most common complications of childbirth and is associated with maternal morbidity and mortality. Here we review the breakthrough development of the first neuroactive steroid-based antidepressants approved for postpartum depression in the USA and their potential in other psychiatric illnesses.</p>","PeriodicalId":22495,"journal":{"name":"The British Journal of Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neurosteroid treatment of postpartum depression and beyond\",\"authors\":\"Kristina M. Deligiannidis, Samantha Meltzer-Brody\",\"doi\":\"10.1192/bjp.2025.90\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Depression occurring during pregnancy or after delivery is one of the most common complications of childbirth and is associated with maternal morbidity and mortality. Here we review the breakthrough development of the first neuroactive steroid-based antidepressants approved for postpartum depression in the USA and their potential in other psychiatric illnesses.</p>\",\"PeriodicalId\":22495,\"journal\":{\"name\":\"The British Journal of Psychiatry\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The British Journal of Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1192/bjp.2025.90\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The British Journal of Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1192/bjp.2025.90","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Neurosteroid treatment of postpartum depression and beyond
Depression occurring during pregnancy or after delivery is one of the most common complications of childbirth and is associated with maternal morbidity and mortality. Here we review the breakthrough development of the first neuroactive steroid-based antidepressants approved for postpartum depression in the USA and their potential in other psychiatric illnesses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
